

References

- *Abdel Gadir A., Khatim M.S., Alnaser H.M.I., Mowafi R.S. and Shaw R.W. (1993):* Ovarian electrocautery responders. *Gynecol Endocrinol*; 7: 4-8.
- *Abdel Gadir A., Mowafi R.S., Alnaser H.M.I., Alonezi O.M., Shaw R.W. (1990):* Ovarian electrocautery versus human gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease. *Clin Endocrinol*; 33: 585-92.
- *Adams J., Poloson D.W. and Franks S. (1995):* Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin-releasing hormone study. *Lancet*; 2: 1375-8.
- *Adams J., Franks S., Poison D.W., Mason H.D., Abdul Wahid N., Tucker M. et al. (1985):* Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin-releasing hormone. *Lancet.*; 2: 1375-9.
- *Adams J., Poison D.W. and Franks S. (1986):* Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *BMJ (Clin Res Ed)*; 293:355-9.
- *Adashi E.Y., Rebar R.W., Ehara Y., Naftolin F. and Yen S.S.C. (1980):* Impact of acute surgical stress on anterior pituitary function in female subjects. *Am J Obstet Gynecol*; 138:609-14.

- **Akin J.W. and Shepard M.K. (1999):** The effect of baseline ovarian cyst on cycle fecundity in controlled ovarian hyperstimulation. *Fertil Steril*; 59: 453-5.
- **Albakry M.M. (1999):** Management of non-responders to clomiphene citrate. *The Egyptian J of Fertility and Sterility*; 3: 223-32.
- **Alborzi S. (1994):** Laparoscopic ovarian cauterization in patients with polycystic ovaries; clinical outcome and endocrine changes. *Iran J Med Sci* 19,120-124.
- **Alborzi S., Khodae R. and Parsanejad M.E. (2001):** Ovarian size and response to laparoscopic ovarian electro-cauterization in polycystic ovarian disease. *Int JGynaecol Obstet.*; 74: 269-74.
- **Al-Ojaimi E.H. (2004):** Endocrine changes after LOD in clomiphene citrate resistant women with PCO. *Saudi Med. J*; Vol.25 (8): 1032-1039.
- **Amer S.A., Banu Z., Li T.C. and Cooke I.D. (2002):** long-term follow up of patients with polycystic ovary syndrome after LOD; endocrine and U/S outcomes. *Human reproduction* Vol. 17, No.11 pp.2851-2857.
- **Andoh A., Mizunuma H. and Liu X. (1998):** A comparative study of fixed dose, step-down and low dose step-up regimens of human menopausal gonadotropins for patient with polycystic ovary syndrome. *Fertil steril*; 70(5): 840-6.
- **Anne B.N. and Ana A.M. (2003):** Diagnostic and operative laparoscopy. In: *Te Lindens Operative Gynecology*. Rock JA, and Ones AW (eds.), (9th edition), Lippincott Williams & Wilkins; 353-78.

- **Api M., Gorgen H. and Cetin A. (2005):** Laparoscopic ovarian drilling in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol; 119(1): 76-81.
- **Armar N.A., Me Carrigle H.H.G., Honour J., Holownia P., Jacobs H.S., Lachelin G.C.L. (1990):** Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrinic changes and clinical outcome. Fertil Steril, 53: 45-49.
- **Armer N.A. and Lachelin G.C. (1993):** Laparoscopic ovarian diathermy, an effective treatment of anti-oestrogen resistant anovulatory infertility in women with polycystic ovary syndrome. Br J Obstet Gynecol; 100(2): 161-4.
- **Bailey C.J. and Puah J.A. (1986):** Effect of metformin and glucose metabolism in mouse soleus muscle. Diabet Metab; 12: 212-18.
- **Balen A. (2006):** Surgical treatment of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab Jun; 20(2):271-80
- **Balen A. (1999):** Polycystic ovary syndrome mode of treatment. In Female infertility therapy: Current practice. Shoham Z, Howles CM and Jacobs H S (eds), (1st edition), Martin Dunitz, London; 45-67..
- **Balen A.H., Braat D.D.M., West C., Patel A. and Jacobs H.S. (1995):** Cumulative conception and live birth rates after the treatment of anovulatory infertility. An analysis of the safety and efficacy of ovulation induction in 200 patients. : Hum Reprod; 9: 1563-70.

- **Balen J. and Jacobs H.S. (1994):** A prospective study comparing unilateral and bilateral laparoscopic ovarian diathermy in women with polycystic ovary syndrome. *Fertil Steril*; 5: 921-5.
- **Bayram N., Van Wely M., Kaaijk E.M., Bossuyt P.M. and Van der Veen F. (2004):** Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. *BMJ*; 328: 192-195.
- **Ben-Jonathan N., Mershon J.L., Allen D.L. and Steinmetz R.W. (1996):** Extrapituitary prolactin: distribution, regulation and clinical aspects. *Endocr. Rev.*; 17:639.
- **Ben-Jonathan N. (1985):** Dopamine: a prolactin-inhibiting hormone. *Endocr. Rev*; 6: 564.
- **Bevan J.S., Webster J., Burke C.W. and Scanlon M.F.:** Dopamine agonists and pituitary tumor shrinkage. *Endocr Rev.*; 13: 220-40.
- **Bilker B.M., Luciano A., Crosignani P.G. et al. (1999):** Guidelines for the diagnosis and treatment of hyperprolactinemia. *J Reprod Med*; 44 (suppl 12): 1075-84.
- **Biller B.M. (1999):** Hyperprolactinemia. *Int J Fertil Womens Med*; 44: 74-7.
- **Biller B.M., Baum H.B., Rosenthal D.I., Saxe V.C., Charpie P.M. and Klibanski A.J. (1992):** Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. *J Clin Endocrinol Metab*; 75: 692-7.

- **Bole-Feysot C., Goffin V., Edery M., Binart N. and Kelly P.A. (1998):** Prolactin and its receptor: action, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. *Endocr. Rev.* 19; 225-268.
- **Bracero N. and Zacur H.A. (2001):** Polycystic ovary syndrome and hyperprolactinemia. *Obstet Gynecol Clin North Am*; 28: 77-84.
- **Brue T. et al. (1992):** Immunoradiometric analysis of circulating human glycosylated and non glycosylated prolactin forms, spontaneous and stimulated secretions. *J. Clin. Endocrinol. Metab*; 75: 1338.
- **Bulun S.E. and Simpson E.R. (1994):** Regulation of aromatase expression in human tissues. *Breast Cancer Res Treat*; 30; 19-29.
- **Campo S. (1998):** Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome. *Obstet Gynecol Surv*; 53(5): 297-308.
- **Chang R.J. and Katz S.E. (1999):** Diagnosis of polycystic ovary syndrome. *Endocrinol metab din North Am.*; 28: 397-8.
- **Chang R.J. (1983):** Hyperprolactinemia and menstrual dysfunction. *Clin-obstet. Gynecol.*; 26:736.
- **Chiara F. (1959):** study of fine innervation of the female reproductive system. *Annali Obstet.Gyne.*; 81; 553-576.
- **Cohen B.M. (1989):** Laser laparoscopy for polycystic ovaries. *Fertil Steril.*; 52: 67-8.

-
- **Cohen J. (2000):** Laparoscopic procedures for treatment of infertility related to polycystic ovary syndrome. Hum Reprod Update; 2: 337-4.
 - **Cohen J. (1996):** Laparoscopic procedures for treatment of infertility related to polycystic ovarian syndrome. Hum Reprod Update; 2: 337-44.
 - **Dahlgren E., Janson P.O., Johansson S., Lapidus L. and Oden A. (1992):** Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand; 71:599-604.
 - **Daniell J.F. and Miller W. (1989):** Polycystic ovaries treated by laparoscopic laser vaporization. Fertil Steril; 51: 232-6.
 - **David F. and Archer (1988):** Hyperprolactinemia. Progress in infertility; 3rd edition chapter 19 p 463.
 - **David M.B. and Schenker J.G. (1982):** Human ovarian receptors to human prolactin : implications in infertility. Fertile. Steril; 38:2.
 - **Del Pozo E., Varga L., Schulz K.D., Kunzig H.J., Marbach P., Del Campo G.L. and Eppenberger U. (1975):** Pituitary and ovarian response patterns to stimulation in the postpartum and in galactorrhea-amenorrhea. The role of prolactin. Obstet Gynecol; 46:539-43.
 - **Delitala G. (1998):** Hyperprolactinaemia: causes, biochemical diagnosis and tests of prolactin secretion. In Clinical Endocrinology Grossman A (ed), (2nd edition), Blackwell Science, Oxford, UK: 138-147.

- **Dewaoiy D. (1997):** Definition and significance of polycystic ovaries. *Bailleres Clin Obstet Gynecol*; 11: 349-68.
- **Diana H.F. and Alison T. (2003):** Anovulation. *BMJ*. 2003; 327: 546-9.
- **Dickey R.P. and Holtkamp D.E. (1996):** Development, pharmacology and clinical experience with clomiphene citrate. *Hum Reprod.*; 2: 483-506.
- **Dickey R.P., Vorys N., Steven V.C. et al. (1965):** Observations on the mechanism of action of domiphen Q. *Ferti! Steril.*; 16:485-94.
- **Dunaif A. (1997):** Insulin resistance and polycystic ovarian syndrome: mechanisms and implications for pathogenesis. *Endocr Rev.*; 18: 774-800.
- **Dunaif A. and Finegood D. (1996):** Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. *J Clin Endocrinol Metab*; 81:942-7.
- **Dunaif A., Hoffman A.R. and Scully R.E. (1985):** Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. *Obstet Gynecol*; 66: 545.
- **Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K. and Imperial J. (1999):** Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care*; 22(1): 141-6.

- *El Saeed M., Ezzat R., Hasan M., Elhelw B., Aboulmaaty Z. and Aboulghar M. (2000):* High incidence of pelvic adhesions detected by second-look laparoscopy after laparoscopic ovarian drilling. Middle East Fertility Society Journal; 5: 519-25.
- *Elsholtz H.P. (1992):* Molecular biology of prolactin: cell specific and endocrine regulators of the prolactin gene. Seminars Reprod. Endocrinol; 10:183.
- *Elting M.W., Korsea T.J.M., Rekers-Mombarg L.T.M. and Schoemaker J. (2000):* Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod; 15: 24-8.
- *Erenus M., Yucelton D., Gurbuz O., Durmusoglu F. and Pekin S. (1996):* Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Fertil Steril; 66: 216-9.
- *ESHRE/ASRM, Rotterdam Consensus Workshop Group (2003):* Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril.; 81:19-25.
- *Farquhar C.M. (2005):* An economic evaluation of laparoscopic ovarian diathermy versus gonadotrophin therapy for women with clomiphene citrate-resistant polycystic ovarian syndrome. curr opin obstet. & gynaec. Aug; 17(4):347-53.
- *Farquhar C., Vandekerckhove P. and Lilford R. (2004):* Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome {Cochrane Review}. John Wiley & Sons, Chichester, UK,1.

- **Farquhar C., Vandekerckhove P. and Lilford R. (2001):** Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. *Cochrane Database Syst Rev*, 4:CD001122.
- **Farquhar C., Vandekerckhove P., Arnot M. and Lilford R. (2000):** Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory Polycystic ovary syndrome. *Cochrane Database Syst Rev*; (2): CD001122.
- **Fauser B., Tarlatz B. and Chang J. (2004):** The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. *Hum Reprod*; 19: 41-7.
- **Fauser B.C., Pache T.D. and Hope W. (1999):** The significance of a single serum Leutenizing Hormone measurement in women with cycle disturbances. *Clin Endocrinol*; 37: 445-52.
- **Felemban A., Tan S.L. and Tulandi T. (2000):** Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. *Fertil Steril*, 73: 266-9.
- **Ferriman D. and Gallwey J.D. (1961):** Clinical assessment of body hair growth in women. *J Clin Endocrinol Metab*; 21: 440-7.
- **Fink R.S., Bowes L.P. and McKintosh C.E. (1982):** The value of ultrasound for monitoring ovarian response to gonadotropin stimulant therapy. *Br J Obstet gynaecol*; 89: 85-6.
- **Franks S. and White D.M. (1993):** Prevalence and aetiological factors in polycystic ovarian syndrome. *Ann NY Acad Scf*; 6: 87-112.

-
- **Frantz A.G., Lienberg D.L. and Noel G.L. (1972):** Studies on prolactin in man. *Recent Prog Horm Res.*; 28: 527-90.
 - **Ganong W.F. (1975):** Neural centers regulating visceral function. In review of medical physiology (9th Ed.) p.164. (Quoted from: prolactin hormone and menstrual disorders; Eman Zekri M. osman; Cairo university 1996).
 - **Gemzel J.C.A., Diczfalusy E. and Tillinger K.G. (1958):** Clinical effects of human pituitary follicle stimulating hormone (FSH). *J Clin Endocrinol Metab*; 18: (12): 1333-48.
 - **Gilling S.C., Willis D.S., Beard R.W. and Ranks S. (1994):** Hypersecretion of andro-stenedione by isolated theca cells from polycystic ovaries. *J Clin Endocrinol Metab.*; 79: 1158- 65.
 - **Gjonnaess A. (1998):** Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. *Fertil Steril*, 69(4):697-701.
 - **Gjonnaess H. (1994):** Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. *Acta Obstet Gynecol Scand.*; 73: 40-4.
 - **Gleicher N. (2000):** Cost-effective infertility care. *Hum Reprod Update*; 6: 190-9.
 - **Goodman Gilman A. (1996):** The pharmacological basis of therapeutics. 9th Ed. McGraw-Hill, New York; 1370-1372.
 - **Gordon A.G. and Magos A.L. (1989):** The development of laparoscopic surgery. *Baillieres Clin Obst and Gynaecol*; 3(3): 429-49.

-
- **Gordon J.S. and Mikhail G. (1979):** Daily plasma prolactin in various gynecologic endocrinopathies. *Fertile-Steril.*; 31-385.
 - **Greenblatt E. and Casper R.F. (1987):** Endocrine changes after laparoscopic ovarian caitary in polycystic ovary syndrome. *AM J Obestet Gynecol.*; 156-279-285.
 - **Gunn S.A. and Gould T.C. (1975):** Vasculature of the adnexa in female reproductive system. *Endocrinol.*; 5; 117-142.
 - **Gurgan T., Kisnisci H., Yarali H., Develioglu O., Zeyneloglu H., and Aksu T. (1991):** Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease. *Ferti Steril*; 56:1176-8.
 - **Haas D.A., Carr B.R. and Attia G.R. (2003):** Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. *Fertil Steril*; 79: 469-81.
 - **Hamilton W.J., Boyd J.D. and Mossman H.W. (1962):** Human embryology. Prenatal development of form and function 3rd ed., Hefer Cambridge.; 1339-1379.
 - **Hammond M.G. and Taubert L.M. (1982):** Clomiphene citrate therapy of infertile women with luteal phase progesterone levels. *Obestet Gynecol.* 1982: 59: 275-279.
 - **Hayashi H., Ezaki K., Endo H. and Urashima M. (2005):** preoperative LH levels predict the ovulatory response to LOD in patients with CCresistant PCOS. *Gynecol Endocrinol.* Dec; 21(6):307-11.

- **Hector F., Escobar M., Manuel L.R. and Jose L.S. (2005):** The molecular-Genetic Basis of Functional Hyperandrogenism and Polycystic Ovary Syndrome. *Endocr Rev.*; 26 (2): 251-282.
- **Hendriks M.L., Ket J.C.F., Hompes P.G.A., Homburg R. and Lambalk C.B. (2007):** Why does ovarian surgery in pcos help? *Human reproduction update*, Vol.13, N3 pp249-264.
- **Herbison A.E. (1997):** Noradrenergic regulation of cyclic GnRh secretion. *Rev. Reprod.*; 2:15.
- **Higa G.M. (2000):** Was altering the estrogenic milieu of breast cancer with focus on the new aromatase inhibitors. *Pharmacotherapy*; 20: 280-91. I
- **Homburg R. (2002):** Should patients with polycystic ovarian syndrome be treated with metformin? *Hum Report*; 17: 853-56. I
- **Hugues J.N., Cedrin-Dumerin I. and Avril C. (1996):** Sequential step-up and step-down' regimen; an alternative for ovulation induction with FSH in polycystic ovary syndrome. *Hum Report*; 11: 2581-4.
- **Hull M.G.R. (1997):** Epidemiology of infertility and polycystic ovarian disease: endocrine logical and demographic studies. *Gynecol Endocrinol*; 1: 235.
- **Imani B., Eijkemans M.J., TeVelde E.R., Habbema J.D. and Fauser B.C. (1998):** Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility; *J Clin Endocrinol Metab.*; 83(7): 2361-5.

- **Insler V., Helmed H. and Eichenbrenner I. (1972):** The cervical score - a simple semi quantitative method for monitoring of menstrual cycle. *Int J Obstet. Gynecol.*; 10:22-3.
- **Inzucchi S.E., Maggs D.G., Spollett G.R. et al. (1998):** Efficacy of metabolic effect of metformin and troglitazone in type II diabetes mellitus. *TV Engl J Med.*; 338: 867-72.
- **Isaacs Jr J.B., Wells C.S., Williams D.B., Odem R.R., Gast M.J. and Strikler R.C. (1996):** Endometrial thickness is a valid monitoring parameter in cycles of ovulation induction with menotropins alone. *Fertil Steril.*; 65: 262-4.
- **Jeffery R. and Chang (1978):** Normal and abnormal prolactin metabolism. *Clin. Obstet. Gyne.*; 21:128.
- **Jenkins R.C. and Ross R.J.M. (1998):** Protocols for common endocrine tests. In: *Clinical Endocrinology*. **Grossman A** (ed), (2nd edition), Blackwell Science, Oxford, UK: 1117-34.
- **Karunakaran S., Page R.C. and Wass J.A. (2001):** The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. *Clin Endocrinol*; 54: 295-300.
- **Keckstein G., Rossmanith W., Spatzier K., Schneider, Borchers K. and Stenier R. (1990):** The effect of laparoscopic treatment of polycystic ovary disease by CO₂-laser or Nd: Yag laser. *Surg Endosc*; 4 (2): 103-7.
- **Kettel L.M. and Hummel W.P. (1996):** Ovulation induction in the oestrogenised anovulatory patient. *Semin Reprod Endocrinol*; 14(4): 309-15.

- **Kidson W. (1996):** Polycystic ovary syndrome: a new direction in treatment. *Med J Aust.*; 114: 122-5.
- **Kletzky O.A. and Davajan V. (1986):** Hyperprolactinemia in infertility, Contraception & Reproductive endocrinology. Medical Economics company inc. Oradell New Jersey USA; Chapter 16: 275.
- **Klibanski A., Biller B.M., Rosenthal D.I., Schoenfeld D.A. and Saxe V. (1988):** Effects of prolactin and estrogen deficiency in amenorrheic bone loss. *J Clin Endocrinol Metab.*; 67: 124-30.
- **Klibanski A., Neer R.M., Beitins I.Z., Ridgway E.C., Zervas N.T., and McArthur J.W. (1980):** Decreased bone density in hyperprolactinemic women. *N Engl J Med.*; 303: 1511-4.
- **Kovacs G.T., Clarke S., Burger H.G., Healy D.L. and Vollenhoven B. (2002):** Surgical or medical treatment of polycystic ovary syndrome: a cost-benefit analysis. *Gynecol Endocrinol*; 16: 53-5.
- **Kriplani A., Manchanda R., Agarwal N. and Nayar B. (2001):** Laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome. *J Am Assoc Gynecol Laparosc*; 8(4): 511-8.
- **Kucuk M. and Kilic-Okman T. (2005):** Hormone profiles and clinical outcome after laparoscopic ovarian drilling in women with polycystic ovarian syndrome. *Med Sci Monit.*; 11(1): 29-34.
- **Laskey M.A. et al. (1998):** Bone changes after 3 months of lactation. *Am Jor. Clini Nutr*; 67:685.

- **Li T.C., Saravelos H., Chow M.S., Chisabingo R. and Cooke I.D. (1998):** Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovary syndrome in women with anovulatory infertility. *Br J Obstet and Gynaecol*; 105(3): 338-44.
- **Lobo R.A., Paul W., March C.M., Granger L. and Kletzky O.A. (1982):** Clomiphene and Dexamethazone in women unresponsive to clomiphene alone. *Obstet Gynecol.*; 60: 497.
- **Luciano A.A. (1999):** Clinical presentation of hyperprolactinemia. *J Reprod Med.*; 44 (suppl 12): 1085-90.
- **Mah P.M. and Webster J. (2002):** Hyperprolactinemia: etiology, diagnosis and management. *Semin Reprod Med*; 20: 365-74.
- **Malkawi H.Y. and Qublan H.S. (2005):** Laparoscopic ovarian drilling in the treatment of polycystic ovary syndrome: how many punctures per ovary are needed to improve the reproductive outcome? *Obstet Gynaecol Res.* Apr; 31(2):115-9.
- **Marcel H.A., Feja J.V., Kaptein M.B.H., Hirasing R.A., Koppenaar C. and Schoemaker J. (2000):** Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns. LH, androgen and insulin. *Fertil Stril.*; 74: 49-58.
- **McClure N., Healy D.L. and Rogers P.A. et al. (1994):** Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. *Lancet.*; 344: 235-6.

-
- **McNatty K.P., Sawers R.S. and McNeilly A.S. (1974):** A possible role for prolactin in control of steroid secretion by the human Graafian follicle. *Nature*, 23(250): 653-5.
 - **Meirow D., Yossepowitch O., Rosier A., Brzezinski A., Schenker J.G. and Laufer N. (1995):** Insulin resistant and non-insulin resistant polycystic ovary syndrome represent two clinical and endocrinal subgroups. *Hum Reprod*; 10: 1951-7.
 - **Melmed S. (1997):** The structure and function of pituitary dopamine receptors, *Endocrinologist*; 7:385.
 - **Micheal T. (2004):** Polycystic ovarian syndrome: diagnosis and management. *Clin Med Res*; 1: 13-27.
 - **Mitvally M.F. and Casper R.F. (2001a):** Aromatase inhibition improves ovarian response to FSH. A potential option for low responders during ovarian stimulation. *Fertil Steril*; 75: 58-9.
 - **Mitvally M.F. and Casper R.F. (2001b):** Use of an aromatase inhibitor for induction ovulation in-patients with an inadequate response to clomiphene citrate, *Fertil Steril.*; 75: 305-9.
 - **Moharram Abdel Haseeb et al. (2007):** Clomiphene citrate and n-acetyl cysteine in treatment of polycystic ovary syndrome. *The journal of the Egyptian society of Obs. And Gyn.* Vol. 33 No.7, 8 & 9.
 - **Molitch M.E. (2001):** Disorders of prolactin secretion. *Endocrinol Metab Clin North Am*; 30: 585-610.
 - **Molitch M.E. (1999):** Medical treatment of prolactinomas. *Endocrinol Metab Clin North Am*; 28 (1): 143-69.

- **Moran L.J., Nooakes M., Clifton P.M. et al. (2003):** Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. *J Clin Endocrinol Metab*; 88: 812-9.
- **Morange I., Earlier A., Pellegrini I., Brue T., Enjalbert A. and Jaquet P. (1996):** Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. *Eur J Endocrinol*; 135: 413-20.
- **Morin P.L.C. (1998):** Treatment of non-responders to clomiphene citrate. *Fertil Steril*; 69:691.
- **Mosgaard B.J., Lidegaard O. et al. (1998):** Ovarian stimulation and borderline ovarian tumours: a case control study. *Fertile Steril*; 70: 1049.
- **Muenstermann U. (2000):** Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. *Hum Reprod*; 15: 2526-30.
- **Mustafa K. and Tulay K. (2005):** Hormonal profiles and clinical outcome after laparoscopic ovarian drilling in women with polycystic ovarian syndrome. *MedSci Monit*; 11(1): 29-34.
- **Naether O.G.J. (1995):** Significant reduction in adnexal adhesions following laparoscopic electrocautery of the ovarian surface by lavage and artificial ascites. *Gynaecol Endosc*; 4: 17-19.
- **Naether O.G.J. and Fischer R. (1993):** Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients. *Fertil Steril*, 60:95-8.

- **Naether O.G.J., Baukloh V., Fischer R. and Kowalczyk T. (1994):** Long-term follow-up in 206 infertility Patients with Polycystic ovary syndrome after laparoscopic electrocautery of the ovarian surface. *Hum Reprod*; 9: 2342-9.
- **Naether O.G.J., Fischer R., Weise H.C., Geiger-Kutzler L., Delfs T. and Rudolf K. (1993):** Laparoscopic electrocoagulation of the ovarian surface in infertile patients with polycystic ovarian disease. *Fertil Steril*, 60: 88-94.
- **Neveu N., Granger L., St-Michel P. and Lavoie H.B. (2007):** Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. *Fertil Steril*; 87: 113-20.
- **Newsome H.H. and Rose J.C. (1971):** The response of human adrenocorticotrophic hormone and growth hormone to surgical stress. *J Clin Endocrinol Metab*, 33:481-487.
- **Nezhat C.R., Nezhat F.R. and Nwzhat C.H. (1995):** Complications of laparoscopic surgery. In: *Progress in reproductive medicine*. Asch R and Stud J (eds), (1st edition), Parthenon Publishing Group Inc, New York, USA; 11: 231-49.
- **Ng E.H.Y. and Ho P.C. (2003):** Ovulation induction. In: *Gynecology*. Shaw RW, Soutter WP and Stanton SL (eds), (3rd edition), vol.1, Churchill Livingstone, Edinburgh, UK: 245-58.
- **Nishioka H., Ito H., Haraoka J., and Hirano A. (2001):** Growth potential of female prolactinomas. *Surg Neurol*; 55: 213-7.

- **Noel G.L., Suh H.K., Stone J.G. and Frantz A.G. (1972):** Human prolactin and growth hormone release during surgery and other conditions of stress. Clin Endocrinol Metab; 35: 840-51.
- **Norman R.J., Davies M.J., Lord J. et al. (2002):** The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol: 13: 251-7.
- **Norman R.J., Wu R. and Stankiewicz M.T. (2004):** Polycystic ovary syndrome. Med J Aust; 180: 132-7.
- **Osijve W., De Boer W., Mulders J.W. and Van Wezenbeek P.M. (1996):** Molecular biology! and biochemistry of human recombinant follicle stimulating hormone. Molt Hum Reprod; 2(5): 371-82.
- **Palomba S., Falbo A., Orio F., Russo T., Sbano F., D'Alessandro P., Cariati F.J., Tolino A., Colao A. and Zullo F. (2006):** Efficacy of laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: relationships with chronological and ovarian age. Gyneco Endocrinol; 22(6): 329-35.
- **Palomba S., Orio F. Jr., Falbo A., Manguso F., Russo T., Cascella T. et al. (2005):** Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in non obese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab; 90: 4068 -74.

- **Parsanezhad M.E., Alborzi S., Zolqhadri J., Parsa-Nezhad M., Keshavarzi G., Omrani G.R. and Schmidt E.H. (2005):** Hyperprolactinemia after laparoscopic ovarian drilling: Unknwon phenomenon, *ReprodBiol Endocrinol*; 7: 3-31.
- **Pirwani I., Sattar N., Packard C.J., Wallace A.M., Fleming R. and Greer (1997):** Lipoprotein subfraction changes in women with oligomenorrhea: relationship to metabolic, hormonal and anthropometric indices. *J Soc-Gynecol invest*; 4(suppl): 90A.
- **Poison D.W., Kiddy D.S., Mason H.D. and Franks S. (1989):** Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responder and non-responders. *Fertil Steril*; 51: 30-34.
- **Quigely M.E. and Ropert J.F. (1981):** Acute prolactin release triggered by feeding. *J. Clin. Endocrinol. Metab*; 52:1043.
- **Rang H.P., Dale M.M., Ritter J.M. and Gardner P. (1995):** Pharmacology. Churchill livingstone Inc; p 422-423.
- **Rebar R.W. (1999):** Following patients under treatment for hyperprolactinemia. *J Reprod Med*; 44 (suppl 12): 1100-1104.
- **Regan L., Owen E.J. and Jacobs H.S. (1990):** Hypersecretion of luteinising hormone, infertility and miscarriage. *Lancet*; 3: 1141-4.
- **Ricardo A.Y., Caros H.Q. and Wael A.S. (1997):** Prolactin disorders. *Fertile. Steril*; (67): 215-25.
- **Richard Snell (1992):** Clinical anatomy, 4th edition 356-357.

- **Robyn C., Delvoe P. and Badawi M. (1977):** Introduction to physiology of human prolactin. Acta Endocrinol 85:1611. (Quoted from: prolactin hormone and menstrual disorders; eman Zekri M. osman ; Cairo university 1996).
- **Royal College of Obstetricians and Gynaecologists (2001):** Green to guideline no.33 long term consequence of polycystic ovary syndrome. 2003 RCOG, London.
- **Saleh A., Morris D., Tan S.L. and Tulandi T. (2001):** Effects of laparoscopic ovarian drilling on adrenal steroids in polycystic ovary syndrome patients with and without hyperinsulinemia. Fertil Steril, 75:501-504.
- **Sallam H.N. (2001):** Infertility and assisted conception (Ed); 57-74.
- **Sallam H.N., Marinho A.O. and Collins W.P. (1982):** Monitoring gonadotrophin therapy by real-time ultrasonic scanning of ovarian follicles. Br J Obstet Gynaecol; 89: 155.
- **Sallam H.N., Scammel G. and Massam G. (1985):** Ovulation and pregnancy after "pure" FSH therapy in sclerocystic ovarian change. Arch Gynaecol; 237: 395.
- **Sanfilippo J.S. (1999):** implications of not treating hyperprolactinemia. J Reprod Med. 44 (12 suppl); 1111-5.
- **Saravelos H. and Li T.C. (1996):** Post-operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with application of interceed to one ovary: a prospective randomized controlled study. Hum Reprod; 11: 992-7.

- **Sharma A., Yousef M., Burrill R. and Atiomo W. (2005):** Recent developments in polycystic ovary syndrome. Progress in obstet. And gynecol. Elsevier, Studd J (Ed.) Vol. 16: 227-39.
- **Shearman R.P. (1969):** Progress in the investigation and treatment of anovulation. Am J Obstet Gynecol; 103(3): 444-63.
- **Sheu W.H., Hsu C.H., Cfaen Y.S., Jeng C.Y. and Fuh M.M. (1994):** Prospective evaluation of insulin resistance and lipid metabolism in women receiving the oral contraceptives. Clin Endocrinol; 40: 249-55.
- **Sinha Y.N. (1995):** Structural variants of prolactin: Occurrence and physiological significance. Endocr. Rev; 16:354.
- **Sinnatamby C.S. (1999):** Abdomen in: Last's anatomy regional and applied (10th edition), 'Churchill Livingstone, Edinburgh, UK: 215-32
- **Slowey M.J. (2001):** Polycystic ovary syndrome; new prospective on an old problem. South Med J.; 94: 190-6.
- **Soules M.R., Sutton G.P., Hammond C.B. and Haney A.F. (1980):** Endocrine changes at operation under general anesthesia: Reproductive hormone fluctuations in young women. Fertil Steril, 33: 364-71.
- **Sowers J.R., Raj R.P., Hershman J.M., Carlson H.E. and McCallum R.W. (1911):** The effect of stressful diagnostic studies and surgery on anterior pituitary hormone release in man. Acta Endocrinol (Copenh). 86:25-32.

- **Speroff L., Glass R.H. and Kase N.G. (1999):** Clinical gynecology, endocrinology and infertility. (6th ed.); Lippincott Williams and Wilkins: Baltimore page 160, 202, 596. And; 21-105:488-521.
- **Stein I.F. and Leventhal M.L. (1935):** Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol, 29, 181-91.
- **Sumioki H., Utsunomyiya T. et al. (1988):** The effects of laparoscopic multiple punch resection of the ovary on hypothalamo-pituitary axis in PCOS. Fertil Steril; 50:567.
- **Takahashi K., Uchida A. and Yamasaki M. (1994):** Transvaginal ultrasonic assessment of the response to clomiphene citrate in polycystic ovary syndrome. Fertil Steril; 62: 48-53.
- **The ESHRS Czpri Workshop Group (2000):** Multiple gestation pregnancy. Hum' Reprod; 15: 1856-64.
- **Togas T. (1996):** Modern surgical approaches to female reproductive tract. Hum Reprod; 2: 419-27.
- **Tolls G., Hickey J., Guyda H. (1975):** Effects of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab; 41: 797-800.
- **Tulandi T., Watkin K. and Tan S.L. (1997):** Reproductive performance and three-dimensional ultrasound volume determination of polycystic ovaries following laparoscopic ovarian drilling. Int J Fertil Womens Med; 42(6): 436-40.

- **Turkingion R.W. (1972):** Measurement of prolactin activity in human serum by the induction of specific milk protein in vitro. Ciba Found. Symp.169 (Quoted from: Prolactin hormone in female fertility and infertility: Abd El-Aziz M.Mahmod. Ain shams university 1981).
- **Tyrrell J.B., Lamborn K.R., Hannegan L.T., Applebury C.B. and Wilson C.B. (1999):** Transsphenoidal microsurgical therapy of prolactinomas: initial outcome and long-term results. Neurosurgery; 44: 254-61.
- **Urman B. and Yakin K. (2006):** Ovulatory disorders and infertility. J Reprod Med. 51(4): 267-82.
- **Van Der Mer, Hompes P.G.A., De Boer J.A.M., Schats R. and Sehoemaker J. (1998):** Cohort rather than FSH hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. J din Endocrinol Me Tab.; 83:423-6.
- **Van Hoff M.H., Van Der Mer M., Lambalk C.B. and Sehoemaker J. (1999):** Variation of leutinizing hormone and androgens in oligomenorrhea and its implications for the study of polycystic ovary syndrome. Hum Reprod; 14; 168-9.
- **Van Wely M., Bayram N. and Van der Veen F. (2003):** Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod.; 18: 1143-9.

- **Van Wely M., Bayram N., van der Veen F. and Bossuyt P.M. (2005):** Predictors for treatment failure after laparoscopic electrocautery of the ovaries in women with clomiphene citrate resistant polycystic ovary syndrome. *Human Reprod*, 20(4): 900-5.
- **Verb Els T.J., Abs R., Maiter D. et al. (1999):** Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. *J Clin Endocrinol Metab*; 84: 2518-22.
- **Vicino M., Loverro G., Bettocchi S., Simonetti S., Mei L. and Elvaggi L. (2000):** Predictive value of serum androstenedione basal levels on the choice of gonadotropin or laparoscopic ovarian electrocautery as ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome. *Gynecol Endocrinol*; 14: 42-9.
- **Webster J. (1999):** Clinical management of prolactinomas. *Baillieres Best Pract Res Clin Endocrinol Metab*; 13(3): 395-408.
- **Webster J. and Scanlon M.F. (1997):** Prolactinomas. In: *Clinical Endocrine Oncology*. Sheaves R, Jenkins PJ, Wass JA (eds), Blackwell Science Publications Ltd, Oxford, UK: 189-94.
- **Webster J. (1996):** A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. *Drug Saf*; 14:228-38.
- **Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I. and Scanlon M.F. (1994):** A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. *N Engl J Med*; 331: 904-9.

- **White D.M., Poison D.W., Kiddy D., Sagle P., Watson H., Gilling-Smitfa C., Hamilton-Fairley D. and Franks S. (1996):** Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. *J Clin Endocrinol Metab*; 81: 3821-4.
- **Williams P.L. and Dyson M. (1992):** Reproductive organs of the female-Gray's anatomy 37th ed.; 1435-70.
- **Wilson C.B. (1997):** Surgical management of pituitary tumors. *Clin Endocrinol Metab.*; 82: 2381-5.
- **Wuttke W., Pitzl L., Seidlova-Wuttke D. and Hinney B. (2001):** LH pulses and the corpus luteum: the luteal phase deficiency LPD. *Vitam Horm*; 63: 131-58.
- **Yildiz B.O., Chang W. and Azziz R. (2003):** Polycystic ovary syndrome and ovulation induction. *Minerva Gynecol*; 55(5); 425-39.
- **Zawadzki J.K. and Dunaif A. (1992):** diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Boston; Blackwell; 337-384.
- **Zukerman S. (1951):** Gonad development and function. Recent progress in hormone research-academic press, New York; 6: 63-109.